Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Poliovirus receptor (PVR) expression as a predictor of relapse in colorectal cancer: bioinformatics and virtual screening.

Experimental biology and medicine (Maywood, N.J.)·2026
Same author

Multi-target therapeutic potential of Neem (<i>Azadirachta indica</i>) phytochemicals in Alzheimer's disease: an integrative network pharmacology and molecular dynamics simulation approach.

In silico pharmacology·2025
Same author

Indazol-Pyrimidine Hybrids: Design, Synthesis, and Antiproliferative Activity Against Human Cancer Cell Lines.

Molecules (Basel, Switzerland)·2025
Same author

Mitigating Cadmium Toxicity: The Therapeutic Potential of Lactobacillus acidophilus Pro4 in Mice.

Probiotics and antimicrobial proteins·2025
Same author

Design, synthesis, biological evaluation and in silico studies of 2-anilino- 4-(benzimidazol- 1-yl)pyrimidine scaffold as antitumor agents.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society·2025
Same author

Synthesis, <i>in vitro</i> and <i>in silico</i> studies of a novel chrysin-ferrocene Schiff base with potent anticancer activity <i>via</i> G1 arrest, caspase-dependent apoptosis and inhibition of topoisomerase II.

Journal of enzyme inhibition and medicinal chemistry·2025

相关实验视频

Updated: Jul 1, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

雷戈拉芬尼:一个全面的药物概况

Ahmed A Abdelgalil1, Hamad M Alkahtani2

  • 1Central Laboratory, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia.

Profiles of drug substances, excipients, and related methodology
|February 29, 2024
PubMed
概括

雷戈拉菲尼布是一种口服的氨酸激酶抑制剂,向VEGF受体,已被批准用于转移性结直肠癌,晚期胃肠道 stromal 瘤和肝细胞癌. 该简介详细介绍了其合成,物理和分析特征以及药理学概况.

关键词:
在 ADME 配置文件中,您可以使用 ADME 配置文件.高性能液体色谱学 高性能液体色谱学化学合成的方法化学合成的方法药理学效应 药理学效应 是一种药理学效应.物理配置文件 物理配置文件雷戈拉费尼布的使用情况稳定的稳定性 稳定的稳定性

更多相关视频

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.7K

相关实验视频

Last Updated: Jul 1, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.7K

科学领域:

  • 药理学 药理学是指药理学的学科.
  • 药用化学 医学化学
  • 药物开发 药物开发

背景情况:

  • 雷戈拉菲尼布是一种口服小分子氨酸激酶抑制剂.
  • 它针对血管内皮生长因子 (VEGF) 受体.
  • 已批准的适应症包括转移性结直肠癌 (CRC),晚期胃肠瘤 (GIST) 和肝细胞癌 (HCC).

研究的目的:

  • 为了提供对regorafenib的全面概况.
  • 整合关于药物合成,物理特征,分析方法和药理学的原始和文献数据.
  • 详细说明药物的特性和制备方法.

主要方法:

  • 文献审查和数据汇编.
  • 对药物合成途径的分析.
  • 物理性质的表征 (例如,可溶性,稳定性,热分析,光谱学).
  • 分析技术的评估 (例如,色谱,光谱,电化学).
  • 吸收,分布,新陈代谢和分泌 (ADME) 概况的评估.

主要成果:

  • 详细描述regorafenib的化学和物理特性.
  • 概述了药物制备的方法和方案.
  • 对质量控制分析方法的全面概述.
  • 讨论ADME概况和药理作用.

结论:

  • 对于理解其治疗应用,Regorafenib的多方面的特征至关重要.
  • 这份个人资料是研究人员和临床医生的宝贵资源.
  • 进一步的研究可以建立在合成数据的基础上,用于药物优化和应用.